FDA may block generic Opana sales

FDA is considering taking regulatory action to prevent the marketing of products containing oxymorphone, such as Opana ER oxymorphone extended release from Endo International plc (NASDAQ:ENDP), FDA Commissioner Scott Gottlieb announced Friday.

In a speech to the National Press Club, Gottlieb noted “media reports in recent days that stated that Endo is participating in a re-launch of the old version of Opana ER” which the company has withdrawn from the market. He was referring to reports that Endo will receive royalties on sales of a generic form of Opana ER from Impax Laboratories Inc. (NASDAQ:IPXL)...